Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Farrell

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2026
An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp StudyKlaus Martin Kortüm, James Farrell, Olivia Ashman, et al.
Gastrointestinal Endoscopy|December 16, 2023
Clinical predictive value of renalase in post-ERCP pancreatitisThiruvengadam Muniraj, Gary Desir, Fred S Gorelick, et al.
Molecular and Clinical Oncology|October 4, 2014
Predominance of ERG-negative high-grade prostate cancers in African American menJames Farrell, Denise Young, Yongmei Chen, et al.
Diagnostic Cytopathology|March 19, 2014
Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: the Papanicolaou Society of Cytopathology guidelinesDaniel Kurtycz, Z Laura Tabatabai, Claire Michaels, et al.
Cytojournal|September 6, 2014
Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology GuidelinesDaniel F I Kurtycz, Andrew Field, Laura Tabatabai, et al.
Radiology|October 2, 2004
Autoimmune pancreatitis: imaging featuresDushyant V Sahani, Sanjeeva P Kalva, James Farrell, et al.
BMC Cancer|August 8, 2025
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial dataMartin Kortüm, Sebastian Theurich, James Farrell, et al.
Patient Preference and Adherence|April 22, 2025
Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel TherapiesSikander Ailawadhi, Yelak Biru, Solène Clavreul, et al.
Leukemia & Lymphoma|July 27, 2023
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myelomaPaula Rodríguez Otero, Kevin Towle, Shannon Cope, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2012
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasiaMitsuro Kanda, Yoshihiko Sadakari, Michael Borges, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2026
An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp StudyKlaus Martin Kortüm, James Farrell, Olivia Ashman, et al.
Gastrointestinal Endoscopy|December 16, 2023
Clinical predictive value of renalase in post-ERCP pancreatitisThiruvengadam Muniraj, Gary Desir, Fred S Gorelick, et al.
Molecular and Clinical Oncology|October 4, 2014
Predominance of ERG-negative high-grade prostate cancers in African American menJames Farrell, Denise Young, Yongmei Chen, et al.
Diagnostic Cytopathology|March 19, 2014
Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: the Papanicolaou Society of Cytopathology guidelinesDaniel Kurtycz, Z Laura Tabatabai, Claire Michaels, et al.
Cytojournal|September 6, 2014
Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology GuidelinesDaniel F I Kurtycz, Andrew Field, Laura Tabatabai, et al.
Radiology|October 2, 2004
Autoimmune pancreatitis: imaging featuresDushyant V Sahani, Sanjeeva P Kalva, James Farrell, et al.
BMC Cancer|August 8, 2025
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial dataMartin Kortüm, Sebastian Theurich, James Farrell, et al.
Patient Preference and Adherence|April 22, 2025
Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel TherapiesSikander Ailawadhi, Yelak Biru, Solène Clavreul, et al.
Leukemia & Lymphoma|July 27, 2023
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myelomaPaula Rodríguez Otero, Kevin Towle, Shannon Cope, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2012
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasiaMitsuro Kanda, Yoshihiko Sadakari, Michael Borges, et al.
Pageof 9